Le Lézard
Classified in: Health, Science and technology, Business
Subject: CXP

Digbi Health's Gut Biome and DNA-Based Weight Loss and Diabetes Management Program Launches with Blue Shield of California

MOUNTAIN VIEW, Calif., Nov. 25, 2019 /PRNewswire/ -- Digbi Health's clinically validated, personalized obesity, pre-diabetes and type 2 diabetes management program tailored to a person's DNA, gut biome, lifestyle preferences, and ethnicity is now available to Blue Shield of California members on the health plan's Wellvolution platform. A digital therapeutics and community health network that is the largest in the industry, Wellvolution was created in collaboration with Solera Health to help consumers holistically manage their health.

Gut microbiome and DNA-Based Weight Loss

Digbi Health's availability on the Wellvolution platform gives Blue Shield members access to a powerful, proven, DNA and gut microbiome-based precision care and personalized lifestyle medicine tool that is tailored to their unique biology and lifestyle.

"Doctors and payers understand that obesity and diabetes are multifactorial diseases, and one-size-fits-all diet and exercise weight loss and diabetes programs do not deliver patient engagement and sustained health results," said Ranjan Sinha, CEO, and founder of Digbi Health. "We are the first company to operationalize a DNA and gut microbiome-based prescription-grade platform for doctors and payers to deliver weight loss and diabetes programs at scale."

"Digbi Health is a strong fit for Wellvolution, which is designed to drive sustained engagement and outcomes by matching members to the program that best meets their needs," said Brenda Schmidt, CEO, Solera Health.

Blue Shield of California, an innovative health insurer with 4.3 million members, launched Wellvolution in June. The digital therapeutics platform, powered by Solera, features a selection of about 70 digital health apps (out of more than 300,000 currently available in the Apple App Store), curated for clinical effectiveness and consumer preference.

About Digbi Health
Digbi Health is a first-of-its-kind precision digital therapeutics (pDTx) company that offers a prescription-grade digitally delivered personalized obesity and diabetes management program based on an individual's gut biome, DNA, blood markers, and lifestyle factors. Digbi Health and members of its precision care MD network are committed to empowering people to take control of their own health and wellness. Digbi Health is prescribed by doctors, health care providers, and insurance companies. Digbi Health is currently conducting three Institutional Review Board approved human studies. Learn more at www.digbihealth.com. Or follow us on LinkedIn, Facebook or Twitter.


SOURCE Digbi Health

These press releases may also interest you

25 sep 2020
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vaxart, Inc. . In early 2020, the Company, which focuses on...

25 sep 2020
Montage Resources Corporation WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation in connection with the proposed acquisition of the company by...

25 sep 2020
The National Society of College Scholars (NSCS) is proud to announce a new community service partnership with The Alzheimer's Association. NSCS members will participate in a community service project through The Alzheimer's Association's Longest Day®...

25 sep 2020
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc.  ("BioMarin" or the "Company") and certain of its officers.   The class action, filed in United States District Court for the Northern District...

25 sep 2020
Century Specialty Script, LLC ("Century"), a specialty pharmacy which provides an array of specific and personalized services in all pharmacy related matters, announced today that it has taken action after learning of a data security incident which...

25 sep 2020
ILJIN SNT Co., Ltd. ("ILJIN SNT") announces that, based on information contained in documents filed publicly by Aurinia Pharmaceuticals Inc. ("Aurinia"), ILJIN SNT has ceased to be an insider of Aurinia. On July 27, 2020, Aurinia completed an...

News published on 25 november 2019 at 09:04 and distributed by: